Price T Rowe Associates Inc. MD boosted its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 88.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,668,056 shares of the company’s stock after buying an additional 16,764,608 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Merck & Company were worth $2,226,043,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Quantitative Systematic Strategies LLC boosted its stake in Merck & Company by 320.6% in the third quarter. Quantitative Systematic Strategies LLC now owns 51,515 shares of the company’s stock valued at $3,193,000 after buying an additional 39,268 shares during the last quarter. Crow Point Partners LLC bought a new stake in Merck & Company during the third quarter valued at about $313,000. Cable Hill Partners LLC boosted its stake in Merck & Company by 36.6% in the third quarter. Cable Hill Partners LLC now owns 8,329 shares of the company’s stock valued at $522,000 after buying an additional 2,230 shares during the last quarter. Gardiner Nancy B bought a new stake in Merck & Company during the third quarter valued at about $424,000. Finally, Cullen Capital Management LLC boosted its stake in Merck & Company by 2.3% in the third quarter. Cullen Capital Management LLC now owns 1,487,815 shares of the company’s stock valued at $92,855,000 after buying an additional 32,745 shares during the last quarter. 74.10% of the stock is currently owned by institutional investors and hedge funds.
Shares of Merck & Company, Inc. (NYSE:MRK) opened at 64.77 on Tuesday. The stock has a market capitalization of $178.58 billion, a price-to-earnings ratio of 31.75 and a beta of 0.79. The stock’s 50 day moving average is $61.76 and its 200-day moving average is $61.81. Merck & Company, Inc. has a 52 week low of $48.28 and a 52 week high of $65.46.
Merck & Company (NYSE:MRK) last posted its earnings results on Thursday, February 2nd. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.00. The firm earned $10.10 billion during the quarter, compared to analysts’ expectations of $10.22 billion. Merck & Company had a return on equity of 24.08% and a net margin of 14.30%. The firm’s revenue was down 1.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.93 earnings per share. On average, analysts anticipate that Merck & Company, Inc. will post $3.81 earnings per share for the current fiscal year.
“Price T Rowe Associates Inc. MD Acquires 16,764,608 Shares of Merck & Company, Inc. (MRK)” was first published by sleekmoney and is owned by of sleekmoney. If you are viewing this piece on another publication, it was illegally copied and reposted in violation of US & international copyright legislation. The correct version of this piece can be viewed at http://sleekmoney.com/price-t-rowe-associates-inc-md-acquires-16764608-shares-of-merck-company-inc-mrk/1659636.html.
Several research firms have recently issued reports on MRK. BMO Capital Markets reiterated an “outperform” rating and set a $70.00 price objective (down previously from $72.00) on shares of Merck & Company in a research report on Wednesday, January 25th. Vetr upgraded shares of Merck & Company from a “sell” rating to a “hold” rating and set a $59.51 price objective on the stock in a research report on Wednesday, January 25th. Bryan, Garnier & Co began coverage on shares of Merck & Company in a research report on Friday, January 13th. They set a “buy” rating on the stock. Jefferies Group LLC reiterated an “underperform” rating and set a $48.00 price objective on shares of Merck & Company in a research report on Thursday, January 12th. Finally, Piper Jaffray Companies upgraded shares of Merck & Company from a “neutral” rating to an “overweight” rating and set a $72.00 price objective on the stock in a research report on Thursday, January 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $66.91.
In related news, EVP Michael J. Holston sold 91,959 shares of the business’s stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $63.96, for a total transaction of $5,881,697.64. Following the completion of the sale, the executive vice president now owns 105,559 shares in the company, valued at $6,751,553.64. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Patricia F. Russo sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 8th. The stock was sold at an average price of $64.42, for a total value of $322,100.00. Following the sale, the director now owns 18,148 shares of the company’s stock, valued at approximately $1,169,094.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 106,959 shares of company stock valued at $6,843,448. 0.05% of the stock is owned by company insiders.
Merck & Company Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/price-t-rowe-associates-inc-md-acquires-16764608-shares-of-merck-company-inc-mrk/1659636.html
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.